Keji biological all human bcma-car t in the treatment of multiple myeloma is approved by FDA clinical trial
-
Last Update: 2020-06-19
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Ct053 car-bcma t is an innovative drug independently developed by Keji biologyIt is a T cell modified by car, which targets B cell mature antigen (BCMA) with all human antibodyIts main target is relapse / refractory multiple myelomaThe clinical trial was approved in the United States, which is the second national or regional clinical license of the product after the implied license of China's National Drug Administration (NMPA) was obtained on February 27, 2019This approval is also the first time for China's original car-t project to independently apply for ind in the United States, and successfully obtained FDA approval< br / > note: the original text has been deleted
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
